1stOncology™: Cancer Intelligence Service – Page 565 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

On September 4, 2025 CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, reported a change of time for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, to Wednesday, September 10, at 9 a.m. EDT (Press release, CytoDyn, SEP 4, 2025, View Source [SID1234655763]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

CytoDyn CFO, Robert E. Hoffman, will deliver a live company presentation and will be available for one-on-one meetings throughout the event, which is taking place September 8-10, 2025, in New York City.

Details of the presentation are now as follows:

Event: H.C. Wainwright 27th Annual Global Investment Conference

Date: September 10, 2025

Time: 9 a.m. EDT

Webcast: register here

Corporate Overview

On September 4, 2025 Cullinan Oncology presented its corportate presentation (Press release, Cullinan Oncology, SEP 4, 2025, View Source [SID1234655762]).

Cidara Therapeutics to Participate in September Investor Conferences

On September 4, 2025 Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, reported that company management will participate in the below September investor conferences (Press release, Cidara Therapeutics, SEP 4, 2025, View Source [SID1234655761]).

Details are as follows:

Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 8, 2025
Time: 4:00 PM ET
Format: Corporate Presentation

Event: Morgan Stanley 23rd Annual Global Healthcare Conference
Date: September 9, 2025
Time: 7:00 AM ET
Format: Fireside Chat

Cidara will also participate in one-on-one investor meetings during the conferences.

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

On September 4, 2025 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA) (Press release, C4 Therapeutics, SEP 4, 2025, View Source [SID1234655760]). BIIB142 is a degrader of IRAK4 that Biogen intends to explore for therapeutic use in patients with autoimmune diseases.

"We are thrilled to see Biogen quickly advance the IRAK4 degrader that resulted from our collaboration toward the clinic in the hopes this molecule may bring a new treatment option to patients with autoimmune disease," said Paige Mahaney, Ph.D., chief scientific officer of C4 Therapeutics. "Our long-standing collaboration with Biogen helped C4T build and deepen capabilities across our platform as we worked together to develop degraders for a broad range of target classes and therapeutic areas to reach a sizeable number of patients with unmet needs. We look forward to Biogen’s continued progress with BIIB142, as well as the second development candidate delivered under our collaboration."

"Our collaboration with C4 Therapeutics has been both powerful and deeply productive, pairing C4T’s expertise in targeted protein degradation with Biogen’s scientific leadership and drug development capabilities," said Jane Grogan, Ph.D., head of research at Biogen. "I’m proud that we have advanced this program based on a cutting-edge modality for a disease with high unmet need, and we see great promise in continuing to pioneer these types of investigational approaches."

Under the terms of the strategic collaboration established in 2018, C4T provided expertise and research services in targeted protein degradation and Biogen provided scientific and drug development capabilities. C4T delivered two development candidates to Biogen under this collaboration. Biogen is responsible for all future clinical development and commercialization for these development candidates. C4T is entitled to receive a $2 million milestone payment upon Biogen dosing patients in the BIIB142 clinical trial.

Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

On September 4, 2025 Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported that Cofounder and Chief Operating Officer, Travis Whitfill PhD MPH, will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City (Press release, Azitra, SEP 4, 2025, View Source [SID1234655757]).

In the prerecorded presentation, Mr. Whitfill will highlight recent updates and progress with Azitra’s pipeline including the announcement of promising safety results for its Phase 1b clinical trial of the ATR-12 program in Netherton syndrome. The Company also recently announced that the first patient has been dosed in the Phase 1/2 clinical trial of the ATR-04 program in EGFR inhibitor ("EGFRi")-associated dermal toxicity in adults. The design for the ATR-04 trial was presented at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Details of the presentation are as follows:

Event:

H.C. Wainwright 27th Annual Global Investment Conference

Date:

September 8-10, 2025

Virtual Presentation:

7:00 AM, ET, September 8, 2025

Presenter:

Travis Whitfill Ph.D., MPH, Cofounder and Chief Operating Officer

Webcast Link:

View Source

During the conference, Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.